Codexis Inc at H C Wainwright Bioconnect Conference (Virtual) Transcript

Jan 10, 2022 / 12:00PM GMT
Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

Thanks for joining us to have a conversation with John Nicols, CEO of Codexis.

Codexis has developed a unique platform called CodeEvolver that helps to take natural enzymes and, with some specific protein engineering steps based on CodeEvolver, develop them into highly efficient enzymes that can be used to improve manufacturing efficiencies in pharmaceutical, food or industrial biotechnology sectors and also generate novel biotherapeutics or even develop life science tools. While sustainable manufacturing has provided a strong base for Codexis, the management has been focusing a lot of their energy recently in life science tools and biotherapeutics.

Happy New Year, John. Glad to see you and appreciate you accepting our invitation to talk to our audience today.

Questions and Answers:

Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot